Sintilimab With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small-cell Lung Cancer: Real-world Data Study

Abstract

\n Purpose:The ORIENT-12 study demonstrated the promising results of sintilimab combined with gemcitabine and platinum (GP) therapy in squamous non-small-cell lung cancer (sqNSCLC) patients. However, the efficacy of sintilimab plus paclitaxel/nab-paclitaxel and platinum (TP) in sqNSCLC is not yet known. Methods: Real-life data were collected from patients with untreated locally advanced or metastatic sqNSCLC who were treated with sintilimab plus TP (arm A) or sintilimab plus GP (arm B) between January 2019 and January 2021. Results:A total of 52 patients were included (arm A, n=32 and arm B, n=20). After a median follow-up of 12.1 months, the median PFS was 10.9 months (95% confidence interval [CI], 5.0 to 16.7) in arm A and 7.5 months (95% CI, 4.0–10.9) in arm B (hazard ratio [HR], 0.64; 95% CI, 0.30 to 1.4; P = 0.24). The median overall survival was 20.1 months (95% CI, 13.6 to 26.6) in arm A and 16.3 months (95% CI, 2.9 to 29.6) in arm B (HR, 0.69; 95% CI, 0.26–1.84; P = 0.46). The overall response rate was 59.4% in arm A and 40.0% in arm B. Adverse events of grade 3 or higher occurred in 37.5% of the patients in arm A and 55.0% of the patients in arm B. Conclusions: Sintilimab-TP exhibits similar clinical benefits compared with sintilimab-GP in patients with untreated advanced or metastatic sqNSCLC.